Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta‐Analysis | Zendy

Lopes L C | Zendy; Spencer F A | Zendy; Neumann I | Zendy; Ventresca M | Zendy; Ebrahim S | Zendy; Zhou Q | Zendy; Bhatnaga N | Zendy; Schulman S | Zendy; Eikelboom J | Zendy; Guyatt G | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta‐Analysis

Author(s) -

Lopes L C,

Spencer F A,

Neumann I,

Ventresca M,

Ebrahim S,

Zhou Q,

Bhatnaga N,

Schulman S,

Eikelboom J,

Guyatt G

Publication year - 2013

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2013.99

Subject(s) - medicine , atrial fibrillation , meta analysis , vitamin k , confidence interval , major bleeding , stroke (engine) , cardiology , mechanical engineering , engineering

Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03–3.11) bleeds per 100 patient‐years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect. Clinical Pharmacology & Therapeutics (2013); 94 3, 367–375. doi: 10.1038/clpt.2013.99

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research